Blinatumomab是一种双特异性T细胞增殖剂(BiTE)。它使患者的T细胞能够识别恶性B细胞。Blinatumomab分子结合两个结合位点:一个T细胞的CD3位点和一个靶B细胞的CD19位点。 Blinatumomab生物仿制药-研究级该产品同种型对照: 缓冲液:ICH3002 浓度:5mg/ml 纯度:>90% by SDS-PAGE 内毒素:≤ 1.0 EU/mg as determined by the LAL method 制剂:Sterile, preservative-free, solution in PBS. BSA and Azide free.